Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTL101 in Pediatric Intractable Epilepsy
NCT02987114Phase 2Completed
- Sponsor
- PhytoTech Therapeutics
- Start
- Feb 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PTL101 in epilepsy, sponsored by PhytoTech Therapeutics. Primary endpoints: Incidence of study treatment related adverse events at 14 weeks and Percent change in mean countable monthly seizure frequency at 12 weeks. Started Feb 2017; status: completed.
02
Drugs
PTL101
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02987114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987114.